Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP 15-19 implementation study of long-acting injectable and oral HIV PrEP in adolescents in Brazil
RBR-104736f4Not yet recruiting
- Sponsor
- Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cabotegravir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo. Primary endpoint: Implementation of PrEP modality choice. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cabotegraviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on RBR-104736f4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-104736f4.